• Science & Technology
    • Technology Overview
  • Medical Applications
    • COVID-19
    • Respiratory Infections
  • Security Applications
    • Security Applications
  • About
    • About Ancon
    • Management Team
    • Papers and Articles
    • News and Events
    • Investors
© All rights reserved.
Ancon Technologies Ancon Technologies
  • Science & Technology
    • Technology Overview
  • Medical Applications
    • COVID-19
    • Respiratory Infections
  • Security Applications
    • Security Applications
  • About
    • About Ancon
    • Management Team
    • Papers and Articles
    • News and Events
    • Investors
Contact Us
Ancon Technologies

COVID-19

Medical Applications - COVID-19

The COVID-19 pandemic has resulted in an urgent need for quick, non-invasive screening technology.

istockphoto-1188952105-612×612

Non-invasive technology for screening and early intervention is key for saving lives.

With 185 million confirmed cases of COVID-19 around the world and 4 million deaths*, access to quick, non-invasive screening technology and early intervention is key for saving lives and reducing the economic impact.

Yet, to date, no breath-based COVID-19 diagnostics have been approved by the FDA or EMA. Ancon’s Machine Learning approach uniquely positions the company to take a leading market position.

*Source:World Health Organization, https://covid19.who.int/, 07/07/21

Futuristic laboratory equipment. Team studying medical samples using microscope

Ancon has developed a powerful proprietary machine learning software: MLBA

Ancon has developed a powerful proprietary machine learning software MLBA (Machine Learning Biomarker Analysis) to rapidly detect patterns of volatile organic compounds (VOCs) the chemicals that accompany virus multiplication in patients and circulate through the respiratory system in breath.We have combined Ancon’s proprietary MLBA with the breath spectra produced from a GC-IMS (G.A.S mbH).

The test procedure is non-invasive, simple and streamlined. Exhaled breath, containing VOCs, is collected via a disposable mouthpiece into a sample tube which is then placed into a desktop GC-IMS. In COVID-19 testing feasibility studies, results achieving clinical accuracy of greater than 90%, with sensitivity of 93% and specificity of 95% have been generated in under 10 minutes through our integrated machine learning algorithm (CoVBreath).

Trials are being conducted in a variety of settings including St Peter’s Hospitals NHS Foundation Trust, a local testing centre near Heathrow Airport in the UK, and the Medical University of South Carolina in the USA.

COVID-19 Diagnostics: Ancon Differentiators

 Ancon Breath TestNucleic Acid Based TestsAntigen TestsAntibody Tests
DetectsVolatile organic compounds
(VOCs)
Viral genetic material (RNA)Proteins on surface of virus
(spike proteins)
Antibodies against virus
Attributes*Confirms active infection,
high accuracy
Confirms active infection, high
accuracy
Confirms active infection,
lower accuracy
Confirms prior infection
SampleExhaled breath; non-invasiveNP / OP swabNP / OP swab, salivaBlood, plasma
Time / CostMinutes $Hours / days $$$Minutes $Minutes $

*The chance that a test is a true positive or a true negative depends not only on a test’s own reliability, but also on background rates of infection and whether a person shows symptoms

Please contact us with any enquiries.

Contact Us

Company

About Us
Contact Us

Information

Privacy Policy and Website Terms of Use

Subscribe to Newsletter
(by clicking subscribe, you agree to our privacy policy)

Ancon logo white

All images used are for reference purposes only.

© 2021 Ancon Technologies
Theme by genapse

in
F.A.Q
Support Forum
Video Tutorials

Search panel can contain any widgets and shortcodes.

Call us: 0 800 255 22 55
We may use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with this. Please review our website privacy policy and terms of use for more information. AcceptPrivacy policy